Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL ) 3.950 -0.060 (-1.50%) Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vigil Neuroscience, Inc. - Common Stock < Previous 1 2 Next > Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi June 27, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present in Upcoming June Investor Conferences May 30, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference May 08, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update May 07, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting April 17, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 26, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer March 20, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting March 13, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days March 12, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024 March 06, 2024 Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to... From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024 February 29, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference February 07, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones January 03, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference November 22, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE November 16, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update November 07, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease October 17, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit October 05, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP September 26, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting September 11, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program September 08, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference September 08, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update August 08, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer August 07, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus July 13, 2023 Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. Via MarketBeat Topics Retirement Exposures Pension Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference June 01, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update May 10, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors May 09, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) May 08, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101 March 30, 2023 Company remains on track to report interim data from Phase 2 trial in the second half of 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.